Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 19.

Journal Article

Demir, M., Nigemeier, J., Kuetting, F., Bowe, A., Schramm, C., Hoffmann, V., Waldschmidt, D., Goeser, T. and Steffen, H-M. (2015). Clinical management of chronic hepatitis B infection: results from a registry at a German tertiary referral center. Infection, 43 (2). S. 153 - 163. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-0973

Demir, M., Nigemeier, J., Kuetting, F., Bowe, A., Schramm, C., Hoffmann, V., Waldschmidt, D., Goeser, T. and Steffen, H-M. (2015). Clinical management of chronic hepatitis B infection: results from a registry at a German tertiary referral center. Infection, 43 (2). S. 153 - 163. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-0973

Galle, P. R., Kim, R. D., Sung, M. W., Harris, W. P., Waldschmidt, D., Cabrera, R., Mueller, U., Nakajima, K., Ishida, T. and El-Khoueiry, A. B. (2020). Updated results of a phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). Ann. Oncol., 31. S. S691 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Giannelli, G., Faivre, S., Santoro, A., Kelley, R. K., Merle, P., Gane, E., Douillard, J. -Y., Waldschmidt, D., Mulcahy, M., Costentin, C., Minguez, B., Papappicco, P. P., Gueorguieva, I., Cleverly, A., Desaiah, D., Lahn, M. M., Ameryckx, S., Benhadji, K. A. and Raymond, E. (2014). EVALUATION OF LY2157299 MONOHYDRATE (LY), A TGF-beta RECEPTOR I KINASE INHIBITOR, IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: PHASE 2 STUDY RESULTS OF SAFETY, EFFICACY AND PK/PD. J. Hepatol., 60 (1). S. S52 - 2. AMSTERDAM: ELSEVIER SCIENCE BV. ISSN 1600-0641

Haas, M., Waldschmidt, D., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R. J. C., Malfertheiner, P., Illerhaus, G., Kubicka, S., Held, S., Westphalen, C. B., Kruger, S., Boeck, S. and Heinemann, V. (2018). Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT). Ann. Oncol., 29. S. 243 - 244. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Hartlapp, I, Valta-Seufzer, D., Siveke, J. T., Algul, H., Goekkurt, E., Siegler, G., Martens, U. M., Waldschmidt, D., Pelzer, U., Fuchs, M., Kullmann, F., Boeck, S., Ettrich, T. J., Held, S., Keller, R., Anger, F., Germer, C. T., Stang, A., Kimmel, B., Heinemann, V and Kunzmann, V (2022). Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113). ESMO Open, 7 (4). AMSTERDAM: ELSEVIER. ISSN 2059-7029

Hartlapp, I., Valta-Seufzer, D., Siveke, J., Alguel, H., Goekkurt, E., Siegler, G. M., Martens, U. M., Waldschmidt, D., Pelzer, U., Fuchs, M., Kullmann, F., Boeck, S., Ettrich, T. J., Held, S., Keller, R., Anger, F., Germer, C-T., Stang, H. A., Heinemann, V. and Kunzmann, V. (2021). Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multi-agent induction chemotherapy: Results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113). Ann. Oncol., 32. S. S1091 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Javle, M., Kelley, R. K., Roychowdhury, S., Weiss, K. H., Abou-Alfa, G. K., Macarulla, T., Sadeghi, S., Waldschmidt, D., Zhu, A. X., Goyal, L., Borad, M., Yong, W. P., Borbath, I., El-Khoueiry, A., Philip, P., Moran, S., Ye, Y., Ising, M., Lewis, N. and Bekaii-Saab, T. (2018). Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. Ann. Oncol., 29. S. 720 - 721. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Kleinert, R., Wahba, R., Waldschmidt, D., Hoelscher, A. and Stippel, D. (2014). Organ specific tumor conference for hepato-biliar diseases - first results after 2 years. Oncol. Res. Treat., 37. S. 93 - 94. BASEL: KARGER. ISSN 2296-5262

Kron, F., Glossmann, J. P., Lotze, M., Barsoum, M., Winters, S., Normolle, D., Boyiadzis, M., Socinski, M., Bernschein, A., Schmidt-Wolf, I., Funke, B., Meyer, M., von Levetzow, C., Leitzke, S., Hellmich, M., Scheid, C., Kreuzer, K. -A., Kostenko, A., Waldschmidt, D., Heukamp, L., Zander, T., Scheffler, M., Hallek, M. and Wolf, J. (2014). A benchmark study of cancer patient outcome in two Comprehensive Cancer Centers in the US and Germany. Oncol. Res. Treat., 37. S. 95 - 96. BASEL: KARGER. ISSN 2296-5262

Perkhofer, L., Striefler, J. K., Sinn, M., Opitz, B., Goetze, T. O., Gallmeier, E., von Weikersthal, L. Fischer, Jacobasch, L., Waldschmidt, D., Niedermeier, M., Sohm, M., Sookthai, D., Berger, A., Beutel, A., Seufferlein, T. and Ettrich, T. J. (2021). Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group. Ann. Oncol., 32. S. S1282 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Quaas, A., Waldschmidt, D., Alakus, H., Zander, T., Heydt, C., Goeser, T., Daheim, M., Kasper, P., Plum, P., Bruns, C., Brunn, A., Roth, W., Hartmann, N., Bunck, A., Schmidt, M., Goebel, H., Tharun, L., Buettner, R. and Merkelbach-Bruse, S. (2018). Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel. BMC Gastroenterol., 18. LONDON: BIOMED CENTRAL LTD. ISSN 1471-230X

Seufferlein, T., Uhl, W., Kornmann, M., Alguel, H., Friess, H., Koenig, A., Ghadimi, M., Gallmeier, E., Bartsch, D. K., Lutz, M. P., Metzger, R., Wille, K., Gerdes, B., Schimanski, C. C., Graupe, F., Kunzmann, V., Klein, I., Geissler, M., Staib, L., Waldschmidt, D., Bruns, C., Wittel, U., Fichtner-Feigl, S., Daum, S., Hinke, A., Blome, L., Tannapfel, A., Kleger, A., Berger, A. W., Kestler, A. M. R., Schuhbaur, J. S., Perkhofer, L., Tempero, M., Reinacher-Schick, A. C. and Ettrich, T. J. (2023). Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)da randomized phase II trial of the AIO pancreatic cancer group. Ann. Oncol., 34 (1). S. 91 - 101. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Sinn, M., Liersch, T., Riess, H., Gellert, K., Stuebs, P., Waldschmidt, D., Lammert, F., Maschmeyer, G., Bechstein, W., Bitzer, M., Denzlinger, C., Hofheinz, R., Lindig, U., Ghadimi, M., Hinke, A., Striefler, J. K., Pelzer, U., Bischoff, S., Bahra, M. and Oettle, H. (2020). CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine plus sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results. Eur. J. Cancer, 138. S. 172 - 182. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Soehngen, D., Balzer, C., Fuchs, M. and Waldschmidt, D. (2015). Rehabilitation of Patients with Acid-base and Fluid Balance Disorders with Short Bowel Syndrome after Ileostomies. Rehabilitation, 54 (2). S. 86 - 92. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-1309

Soehngen, D., Balzer, C., Fuchs, M. and Waldschmidt, D. (2015). Rehabilitation of Patients with Acid-base and Fluid Balance Disorders with Short Bowel Syndrome after Ileostomies. Rehabilitation, 54 (2). S. 86 - 92. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-1309

Waldschmidt, D., El-Khoueir, A. B., Kim, R. D., Harris, W. P., Sung, M. W., Iqbal, S., Zhang, A., Nakajima, K. and Galle, P. R. (2020). Phase 1b study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). Oncol. Res. Treat., 43 (SUPPL 4). S. 123 - 124. BASEL: KARGER. ISSN 2296-5262

Waldschmidt, D., Merle, P., Granito, A., Huang, Y-H, Bodoky, G., Yokosuka, O., Rosmorduc, O., Breder, V. V., Gerolami, R., Masi, G., Ross, P. J., Qin, S., Song, T., Bronowicki, J-P, Ollivier-Hourmand, I, Kudo, M., Xu, L., Baumhauer, A., Meinhardt, G., Han, G. and Bruix, J. (2018). Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib. Oncol. Res. Treat., 41. S. 281 - 282. BASEL: KARGER. ISSN 2296-5262

Waldschmidt, D., Teufel, M., Koechert, K., Meinhardt, G. and Bruix, J. (2018). Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis. Oncol. Res. Treat., 41. S. 281 - 283. BASEL: KARGER. ISSN 2296-5262

This list was generated on Fri Mar 29 09:12:29 2024 CET.